Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 6/20 | 0.52 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 4/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.44 |
| ▸ | HTR3B | O95264 | 2/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335076 | 0.78 | ALDH1A1 (0.43) | HTR2CLMNAMAPT | |
| SCHEMBL5335779 | 0.78 | ALDH1A1 (0.43) | HTR2CLMNAMAPT | |
| SCHEMBL11633494 | 0.74 | ADRB1 (0.41) | ADRB1HTR7HTR2CHTR3AHTR3E | |
| SCHEMBL2875718 | 0.73 | ADRB1 (0.47) | ADRB1HTR7HTR2CHTR3AHTR3E | |
| SCHEMBL31651815 | 0.73 | ROCK2 (0.43) | ADRB1HTR7HTR2CDRD2DRD3 | |
| SCHEMBL27856214 | 0.73 | DRD2 (0.51) | ADRB1DRD2DRD3HTR1ALMNA | |
| SCHEMBL5371831 | 0.73 | HTR2C (0.41) | HTR2C | |
| SCHEMBL21775839 | 0.73 | ADRB1 (0.47) | ADRB1HTR7HTR2CHTR3AHTR3E | |
| SCHEMBL5336556 | 0.73 | HTR2C (0.41) | HTR2C | |
| Hydrochloric Acid SCHEMBL7923474 | 0.72 | ADRB1 (0.46) | ADRB1HTR7HTR2CHTR3AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | UNIV JOHNS HOPKINS (US) | 2026-04-02 | — | — | US | disclosed |
| US-12527746-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4642434-A2 | LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | Life Technologies Corporation (US) | 2025-11-04 | — | — | US | disclosed |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250136737-A1 | MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS | THE JOHNS HOPKINS UNIVERSITY | 2025-05-01 | — | — | US | disclosed |
| US-20240263196-A1 | Lipid Compositions and Methods for Delivery to Immune Cells | Life Technologies Corporation | 2024-08-08 | — | — | US | disclosed |
| US-12049530-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERISTY (US) | 2024-07-30 | — | — | US | disclosed |
| WO-2024145435-A2 | LIPID COMPOSITIONS AND METHODS FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4247895-A1 | POLY ACRYLATE AND POLY(BETA-ESTER) CAPSULES WITH ENHANCED DEGRADABILITY | Encapsys, LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| US-6028195-A | AN ANTITUMOR AGENT WITH VERY LOW TOXICITIES | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2000-02-22 | — | — | US | disclosed |
| WO-1999016779-A1 | 3'-N-MODIFIED 6-O-SUBSTITUTED ERYTHROMYCIN KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | ABBOTT LABORATORIES (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999011651-A2 | 3-DESCLADINOSE 6-O-SUBSTITUDED ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-03-11 | — | — | WO | disclosed |
| US-5866549-A | MACROLIDE ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0878194-A1 | REMEDIES OR PREVENTIVES FOR AIDS | SANKYO COMPANY LIMITED (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5688795-A | URINARY TRACTS OBSTRUCTION | SYNTEX (U.S.A.) INC. (US) | 1997-11-18 | — | — | US | disclosed |
| CN-1152916-A | Trifluoromethylquinoline carboxylic acid derivative | UBE INDUSTRIES (JP) | 1997-06-25 | — | — | CN | disclosed |
| EP-0773214-A1 | TRIFLUOROMETHYLQUINOLINECARBOXYLIC ACID DERIVATIVE | UBE INDUSTRIES, LTD. (JP) | 1997-05-14 | — | — | EP | disclosed |
| EP-0711757-A1 | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists | F. Hoffmann-La Roche AG (CH) | 1996-05-15 | — | — | EP | disclosed |
| US-3947446-A | HYPOTENSIVE | BOEHRINGER MANNHEIM GMBH (DT) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527746-B2 | Peptide/particle delivery systems | VEGFA, IGF2BP2, MSTN | ADRB1 1326/4885HTR7 1145/4885HTR2C 3732/4885 |
| US-20250136737-A1 | MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS | PEF1, FIBP, PARN | ADRB1 4466/4885HTR7 1197/4885HTR2C 2124/4885 |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | SNRPA, NUDT21, SOAT2 | ADRB1 2390/4885HTR7 826/4885HTR2C 2953/4885 |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | AARS1, SLC43A1, PHAX | ADRB1 1085/4885HTR7 3448/4885HTR2C 4754/4885 |
| US-12049530-B2 | Multicomponent degradable cationic polymers | PEF1, FIBP, PARN | ADRB1 4466/4885HTR7 1197/4885HTR2C 2124/4885 |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | SLC43A1, SLC7A5, SLC7A1 | ADRB1 961/4885HTR7 4194/4885HTR2C 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.